Take Control of Your Leukaemia Journey with Advanced MRD Monitoring
When you’re navigating leukaemia treatment, the uncertainty about whether cancer cells remain can be overwhelming. Our INV16 Gene Rearrangement Quantitative MRD Monitor Test provides the clarity and confidence you need to move forward with your life. This isn’t just another test – it’s your partner in maintaining remission and catching any changes early, when treatment options are most effective.
Understanding Your MRD Monitoring Test
The INV16 Gene Rearrangement test specifically tracks the INV16 chromosomal abnormality, which is associated with certain types of acute myeloid leukaemia (AML). Think of it as a highly sensitive radar system that can detect even the smallest number of remaining cancer cells – what we call minimal residual disease (MRD). Unlike standard tests that might miss these tiny amounts, our quantitative monitoring gives your medical team precise measurements to guide your ongoing care.
Who Should Consider This Essential Monitoring?
This test is specifically designed for patients who have been diagnosed with INV16-positive acute myeloid leukaemia and are either:
- Currently undergoing treatment and need regular monitoring
- In remission and want to ensure they stay cancer-free
- Experiencing concerning symptoms that might indicate relapse
- Working with their oncologist to determine the most effective long-term treatment strategy
Why Early Detection Matters for Your Health
Finding leukaemia cells early, before they multiply significantly, can make all the difference in your treatment success. Early detection means:
- More treatment options available
- Higher likelihood of successful intervention
- Reduced treatment intensity in many cases
- Greater peace of mind for you and your loved ones
- Better long-term health outcomes
Understanding Your Results with Confidence
Your results will show the quantity of INV16-positive cells detected, measured with exceptional precision. Your oncologist will explain what these numbers mean for your specific situation and help you understand the next steps. Remember – a positive result doesn’t necessarily mean treatment has failed; it means we’ve caught any changes early, when they’re most manageable.
Transparent Pricing – Investing in Your Health
| Test Description | Regular Price | Special Price | Savings |
|---|---|---|---|
| INV16 Gene Rearrangement Quantitative MRD Monitor | ZAR 3,350 | ZAR 2,500 | ZAR 850 |
Consider this: early detection of relapse can save thousands in future treatment costs and, more importantly, preserve your quality of life. This test represents one of the most valuable investments you can make in your ongoing health.
Nationwide Access to Expert Care
We understand that travel can be challenging during treatment. That’s why we offer convenient testing locations across South Africa, including Johannesburg, Cape Town, Durban, and Pretoria. Our network ensures you can access this crucial monitoring without adding stress to your recovery journey.
Your Next Step Towards Peace of Mind
Don’t let uncertainty about your remission status create unnecessary anxiety. Take proactive control of your health with the most advanced MRD monitoring available. Our team at Oracle Genomics is here to support you every step of the way with compassionate, expert care you can trust.
Ready to take the next step in your leukaemia journey? Contact us today to schedule your test or speak with our patient care specialists about how this monitoring can benefit your specific situation. Your health deserves the best monitoring available.
Important Note: This test requires a duly filled MRD Requisition form (Form 22) with your historical data. Samples are processed Mondays and Thursdays by 11 AM, with results available Wednesdays and Saturdays.
